Lates News

According to AI Fast News, Huaxin Securities released a research report on August 28th, giving a buy rating to Mindray Medical (688016.SH). The reasons for the rating mainly include: 1) the domestic market is under pressure, but the product structure is optimized, and it is expected to achieve the 25-year equity incentive target; 2) the overseas market continues to show high growth momentum, and the innovative product pipeline builds long-term barriers. (Daily Economic News)